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Abstract: While the mammalian eye is seldom considered an organ of drug metabolism, the 
capacity for biotransformation is present. Compared to the liver, the metabolic capabilities 
of the eye are minuscule; however, phase I and phase II metabolic activities have been 
detected in various ocular structures. The careful consideration of ocular tissue metabolic 
processes within the eye has important implications for controlling the detoxification of 
therapeutic agents and for providing the potential for site-specific bio-activation of certain 
drug molecules, thus enabling significant improvements in drug efficacy and the 
minimization of side-effect from either local or systemic drug delivery to the eye. 
Knowledge of these processes is important to prodrug and codrug development and to 
researchers involved in the design, delivery and metabolism of ophthalmic drugs. This 
present article reviews the progress in ocular prodrug and codrug design and delivery in 
light of ocular metabolic activities. 
Keywords: Ocular metabolism, drug delivery, drug design, phase I biotransformation, 
phase II biotransformation. 
 
Introduction  
One might consider the eye an ideal, easily accessible target organ for drug delivery. However, the 
eye is, in fact, well protected against absorption of foreign materials (i.e. drugs and xenobiotics), first 
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by the eyelids and tear-flow, and then by the cornea and conjunctival epithelial barriers of the eye [1]. 
Furthermore, although the mammalian eye is seldom considered an organ of drug metabolism, in this 
respect, phase I and phase II biotransformation activities have been detected in various ocular 
structures. These metabolizing capabilities of the mammalian eye are unique in providing protection 
from xenobiotics and foreign compounds.   
A drug applied to the surface of the eye may cross ocular–blood barriers where it may encounter 
metabolizing enzymes and cellular transporters before it distributes to the site of action. Other 
problems of drug delivery to the eye include: poor bioavailability of ophthalmic solutions, clearance 
and drainage from the eye (ophthalmic drugs typically achieve < 10% ocular bioavailability), side 
effects resulting from ophthalmic drugs reaching the systemic circulation, decreased visual acuity, and 
patient compliance. 
Currently there is considerable interest in ophthalmic drug design based on strategies to improve 
ophthalmic drug delivery through metabolic activation. As ocular enzymes and transport systems are 
better characterized, their properties become an integral consideration in drug design and development. 
Various review articles have been published to date describing the strategies employed for enhancing 
ocular drug delivery [2-6] but only a few studies have addressed phase I and phase II ocular metabolic 
activity and their utility in metabolism-focused, ophthalmic-specific drug design. This specific area is 
the focus of this review. 
 
1. Anatomy of the Eye 
 
1a. Blood Flow and Membrane Properties of the Eye 
 
Most ocular tissues have a rich blood supply, except for the cornea and lens. The retina receives its 
blood supply from the retinal artery, which enters the eyeball along the optic nerve. The outer layer of 
the retina is adherent to the choroids, which is a highly vascular tissue that supplies the outer segment 
of the retina, as well as the rest of the optic structures with nutrients and oxygen; this is known as the 
uveal blood supply [7]. 
Because of this rich blood supply, the eye must have a way to regulate the entrance of circulating 
compounds and a way to transport metabolic by-products and/or toxicants out of the eye [8]. The 
blood-ocular barrier, which functions in a similar manner as the blood-brain barrier, restricts the entry 
of many compounds and thereby maintains homeostasis in the eye. The blood-ocular barrier can be 
separated into two distinct barriers; the blood-vitreous barrier and the blood-retinal barrier. The blood-
vitreous barrier includes the ciliary epithelium, retinal pigment epithelium, and blood vessels of the 
retina. The blood-retina barrier involves primarily the retina. 
 
1b. Transport and Distribution Mechanisms in the Eye 
  
Blood-ocular barriers are important for reasons other than just the removal of toxic waste products 
and xenobiotics. The eye requires nutrients just like any other organ in the body, and thus requires 
selective transport mechanisms. There are three major sites of transport for polar nutrients into the eye: 
the uvea, which consists of the ciliary body and iris, the retina, and the lens [8]. Several studies have 
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been conducted to determine the degree of specificity of ocular transport systems. Common transport 
systems are known to exist for structurally similar amino acids; for instance L-phenylalanine and L-
leucine share a common transport system. This may be a mechanism by which many xenobiotics are 
transported into the eye, as well as a way to deliver pharmacological agents to the eye for the treatment 
of ophthalmic disorders.  
The eye is usually overlooked in tissue distribution studies during drug development. Although the 
levels of drug and/or metabolite are usually low in most ocular tissues, due to the presence of the 
blood-ocular barrier discussed above, there are several examples of peripherally administered drugs 
causing side effects in ocular tissues. Chloroquine is an example of an antimalarial drug that affects the 
cornea after oral administration, resulting in intolerance to glare and halos around lights [9]. Another 
drug, chlorpromazine, results in lens deposits and pigmentary retinopathy after systemic administration, 
[10]. Tamoxifen administration also results in corneal deposits; however, this is due to its insolubility 
in tear solution. The active metabolite of acetaminophen, N-acetyl-p-benzoquinone imine, has been 
found to bind to ocular tissues, resulting in cataract formation [9].  
The mode of administration of a drug can be an important factor in determining ocular tissue 
distribution. Studies of single dose parenteral administration of pentobarbital, aspirin, and three 
antibiotics showed that the highest drug levels were found in the cornea and iris, and in some studies in 
the retina and conjunctiva. Drug concentrations in the choroid, sclera, and retina were intermediate, 
with the aqueous and vitreous humors and lens tissue having the lowest concentrations. There is a 
serious lack of data on drug/metabolite concentrations in the ciliary body after parenteral drug 
administration, an ocular tissue that is known to concentrate drugs, as well as having marked 
metabolizing capability. Studies carried out after topical application of drugs have revealed that the 
ciliary body is usually intermediate, and in one case, is low in drug concentration [8].   
In elimination studies, several drugs have been shown to clear more slowly from the eye compared 
to other tissues [11]. The iris, retina, choroids, and uveal tract are the tissues that result in most drug 
accumulation, and slow elimination has been associated with drugs binding to melanin, the pigment 
epithelium.  
 
2. Metabolic Activity in the Eye 
 
2a. Phase 1 metabolic activity in the eye 
  
Because the eye is an important site of exposure to xenobiotics, it is not surprising that it would 
possess enzymes capable of metabolizing such foreign species. The eye displays a regional distribution 
of Phase 1 metabolic activities toward endogenous and xenobiotic substrates. In general, these 
activities are highest in those ocular structures adjacent to regions of highest uveal blood flow. 
Cytochrome P-450 activity has been identified by characteristic differential carbon monoxide-binding 
spectra; the difference in spectra obtained between carbon monoxide bound and reduced microsomes 
of bovine ciliary body and cornea [12,13]. In these studies microsomes were prepared from bovine 
ciliary bodies. The cytochrome P-450 contents and related components of the microsomal electron 
transport system have been determined to be 32 pmoles/mg protein, which is about 4% that found in 
rat liver.  
Molecules 2007, 12  
 
 
376
Cytochrome P450-dependent metabolism of endogenous substrates (arachidonic acid, 
prostaglandin and steroids) in the eye has been demonstrated [14,15]. P-450-dependent arachidonic 
acid was found to primarily occur in the corneal epithelium, but detectable activity was also found in 
the retina, retinal pigment epithelium and ciliary body [14]. Prostaglandin hydroxylase-(omega/omega-
1) activities were detected by Asakura and Shichi primarily in ciliary body epithelium [15]. Research 
by Shichi et al, generated the earliest reports documenting the presence of cytochrome P-450-
dependent aryl hydrocarbon hydroxylase activity in the eye [16,17]. Further research by this laboratory 
and others demonstrated that ocular tissues display substrate-dependent differences in activities in 
various ocular regions, which is indicative of the presence of multiple forms of cytochrome P-450 
distributed heterogeneously [13,18,19].  
Table 1 identifies those cytochrome P-450-dependent activities reported to be present in the eye 
and their location. Schwartzman et al. measured aryl hydrocarbon hydroxylase (AHH), 7-ethoxy-
coumarin-O-deethylase (ECOD) and benzphetamine demethylase (BPDM) in bovine ocular tissues 
[14]. These authors reported that the highest levels of AHH occurred in the ciliary body and were five 
(retinal pigment epithelium) and ten (retina or corneal epithelium) times higher than in other 
ophthalmic tissues. ECOD activity was highest in the retinal pigment epithelium, then in decreasing 
levels of activity; ciliary body, corneal epithelium, retina and corneal endothelium. BPDM activity was 
only detected in retinal pigment epithelium and ciliary body tissue. Cytochrome P-450-dependent 
activities in ocular tissues are inducible by the “classical” p450 inducers, phenobarbital (PB) and 3-
methylcholanthrene (3-MC), and by clofibrate and hypoxia. Based on the induction of specific 
activities by different inducers, the presence of particular cytochrome P-450 isoforms may be deduced 
[20].  
 
Table 1. Cytochrome P-450-dependent metabolism in ocular tissues. 
Enzyme Substrate Ocular Tissue Ref. 
7-Ethoxyresorufin-O-
dealkylase (EROD) 
7-Ethoxyresorufin Porcine ciliary body, and bovine ciliary body 18, 10 
7-Pentoxyresorufin-O-
dealkylase (PROD) 
7-Pentoxyresorufin Porcine ciliary body, and bovine ciliary body 18, 10 
7-Ethoxycoumarin O-
deethylase (ECOD) 
7-Ethoxycoumarin Bovine corneal epithelium, retinal pigment 
epithelium, retina, ciliary body and corneal 
epithelium 
12, 14 
Aryl hydrocarbon 
hydroxylase (AHH) 
Benzo(a)pyrene Bovine retina, cornea, iris, choroid, ciliary 
body; Bovine retinal pigment epithelium, 
corneal endothelium; Mouse eye; Chick 
embryo retinal pigmented epithelium 
12, 14, 
15 
Benzphetamine demethylase 
(BPDM) 
Benzphetamine Bovine retinal pigment epithelium, and ciliary 
body 
12, 14 
Prostaglandin hydroxylase Prostaglandin Porcine iris, ciliary body 13 
Cyclooxygenase 
 
Arachidonic acid Bovine and rabbit corneal epithelium; Bovine 
corneal epithelium, ciliary body and corneal 
endothelium 
12,16 
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Other phase 1 activities in the eye have been detected by immunohistochemical methods or by 
metabolic activities toward specific substrates. Like the cytochrome P-450 monooxygenases, these 
other enzyme systems show various levels of activity and heterogeneous distribution throughout the 
ocular tissues. Monoamine oxidase has been detected by histochemistry in the optic and ocularmotor 
nerves, ciliary epithelium, pigmented epithelium and the plexiform layer of rabbit retina [21]. 
Monoamine oxidase activities toward β-phenylethylamine have been detected in bovine retina [22]. 
Diamine oxidase activity has been reported to be present in bovine aqueous humor using p-
dimethylaminomethyl benzylamine as substrate: this activity was not detected in the lens, cornea 
vitreous or sclera [23]. Kremzner et al. reported the presence of the physiological substrates of diamine 
oxidase, i.e. putrescine, spermine and spermidine, in the lens [24], despite the lack of activity reported 
by Crabbe [23] in lens tissues. The hydrolysis of dipivefrin, an ester prodrug of epinephrine, has been 
reported to occur in rabbit corneal homogenates [25], yielding the active drug. 
Sanchez-Chavez et al. studied the acetylcholinesterase (AChE) and butyrylcholinesterase (BChE) 
activities in the neural retina and retinal pigment epithelium (RPE) of adult rats and showed that 
amphiphilic tetramers and monomers of AChE are abundant in neural retina, and enzyme tetramers, 
dimers, and monomers in RPE.  It was suggested that the AChE in the neural retina might be involved 
in cholinergic actions [26].   
β-Glucuronidase activity has been reported in ocular tissues of man, rabbit, and guinea pig [27]. 
The activities of β-glucuronidase and other hydrolases in the anterior segment tissues of human, pig 
and rat eyes were determined and reported in the cornea, ciliary epithelium and iris [28]. These same 
authors examined hydrolase activities in the trabecular meshwork of normal and glaucomatous eyes; 
they found increased levels of nonspecific esterases, γ-glutamyl transpeptidases and aminopeptidases 
in trabecular from glaucoma patients when compared to controls [29]. It was also reported that 
increased hydrolase activities occur in the inflamed eye [30]. 
Oxidoreductases have been found in ocular tissues of many different human sources species. Zeta-
crystalline, a lens protein in the Guinea pig, exhibits NADPH-dependent oxidoreductase activity with 
2, 6-dichlorophenolindophenol [31]. Aldehyde dehydrogenases have been reported to occur in many 
different tissues of the mammalian eye, including humans. These enzymes occur in many isoforms 
with different substrate affinities [32,33]. The aldehyde dehydrogenases of the ocular tissues have been 
proposed to be involved in lipid peroxidation, ethanol metabolism, carbohydrate metabolism and the 
visual cycle of the retina [34].  
 
2b. Phase II metabolic activity in the eye 
  
Several studies have shown that various tissues of the eye are capable of Phase II conjugation 
activity. One of the most comprehensive studies was carried out by Watkins et al. using rabbit ocular 
tissues [35]. Five tissues of the eye, including lens, choroids, iris, retina, and cornea, were assayed for 
N-acetyltransferase, glutathione-S-transferase, UDP-glucuronosyltransferase, and 2-naphthol sulfo-
transferase activities. The iris/ciliary body had the highest glutathione S-transferase activity, while the 
cornea exhibited the highest specific activities for N-acetyl-, sulfo-, and UDP-glucuronosyl-
transferases. The lens was the only tissue tested that did not have any significant phase II 
biotransformation capacity. In addition, ocular activity for these Phase II enzymes has been compared 
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to that of liver and other extra hepatic organs. The N-acetyltransferase activity in the iris/ciliary body 
was nearly as high as that in liver, kidney, or intestine, whereas the glutathione S-transferase activity 
in the cornea and iris/ciliary body was 70 and 89%, respectively, of the activity in the intestine, and 
sulfotransferase activity of the cornea was greater than the same activity measured in the kidney. 
These results support the hypothesis that the eye is susceptible to exposure to endogenous and 
exogenous substrates, and therefore must possess the capacity for detoxification biotransformation. 
The cornea is particularly susceptible to exogenous exposure to xenobiotics and/or irritants; therefore, 
biotransformation activity could serve as a first line of defense. It is known that the cornea can tolerate 
high concentrations of topically applied compounds. Likewise, the lack of metabolic activity present in 
the lens is not surprising, given the limited blood supply to this tissue. Even though the majority of the 
protein content exists in the lens, the primary protein of the lens is α-crystalline, which has little or no 
metabolic capability. Glutathione is present in the lens; without which the presence of significant 
levels of potentially harmful xenobiotics can occur.  
Earlier work by Saneto et al. revealed the presence of all enzymes involved in glutathione S-
transferase activation, i.e. γ-glutamyl transpeptidase, cysteinylglycinase, and N-acetyl transferase, in 
bovine ocular tissues, including lens, cornea, retina, and retinal pigmented epithelium [36,37].  
Ahmad et al. compared the structural relatedness of bovine glutathione S-transferase to the three 
classes of human glutathione S-transferase, i.e. alpha, mu, and pi [38]. Using immunoblotting 
techniques, expression of these isozymes was examined in the lens, cornea, and retina. It was observed 
that the various isozymes were expressed in a tissue-specific manner, due to the specific functional 
needs of these various ocular tissues. The individual isozymes of glutathione S-transferase are known 
to carry out particular functions, e.g. the alpha class is thought to be involved in protection of the 
tissues from oxidative damage via glutathione peroxidase-2 activity. However, Saneto et al. in an 
earlier study purified two isozymes of glutathione S-transferase from bovine retina and showed that the 
retina did not contain selenium-dependent glutathione peroxidase activity [37]. N-acetyl transferase 
activity has been identified in the retina of male Sprague Dawley rats [39]. These authors used 
tryptamine to demonstrate the presence of N-acetyl transferase in retinal homogenates from rat. The 
rate of tryptamine acetylation varied over a 24 h period with maximal activity occurring around noon.  
Enzymatic step-wise methylation of membrane phosphatidylethanolamine (PE) to phosphatidyl-N-
methylethanolamine (PME) and then phosphatidylcholine (PC) has been shown to alter membrane 
properties and responsiveness of cells for activation of receptors by chemical transmitters. The 
conversion of PE to PME and PME to PC in the presence of S-adenosyl-L-methionine (SAM) are both 
catalyzed by two phospholipid N-methyltransferases, PMT I and PMT II, of which PMT I is the rate 
limiting enzyme.  The retina is a good neuronal model for chemical transmission and it was found that 
rat retina contains both PMTs and fatty acid carboxymethylase (FACM) [40]. 
 
3. Metabolism-focused Ophthalmic-specific Drug Design and Delivery Systems 
 
As described above, most ophthalmic drugs were not originally developed for the treatment of eyes; 
such drugs were originally intended for other therapeutic areas and were adopted for ophthalmic drugs 
by virtue of accidental observation of efficacy in eye disease. For these reasons, there is considerable 
interest and a need for improved ophthalmic drug delivery strategies. The current trend in ophthalmic 
Molecules 2007, 12  
 
 
379
drug design is based on the drug metabolism properties of the eye, which include the prodrug and 
codrug approach, retro-metabolic drug design approaches; chemical delivery (CD) and soft drug (SD) 
systems. In this review article we will discuss recent development in the area of ocular prodrug and 
codrug design. 
 
3a. The Prodrug Approach  
 
The prodrug approach is one of the most promising and viable strategies currently being 
investigated for ophthalmic drug delivery. One aspect of current research in ophthalmic drug delivery 
is focusing on the design of ophthalmic prodrugs which explore the drug metabolism capability of 
ocular tissues. The cornea epithelium and endothelium contain 100-fold greater amount of lipid 
material per unit weight than the hydrophilic stroma [41]. Lipophilic drugs absorb into epithelial tissue, 
but their partitioning from the epithelium to the stroma may become a penetration-limiting factor [42]. 
Consequently, adequate solubility both in epithelium and stroma is required. One way to achieve 
biphasic solubility is to design lipophilic prodrug that can be converted to more hydrophilic derivative 
or parent drug in the epithelium.  
The prodrug approach has been utilized to enhance the ocular delivery of pilocarpine [43-46]. 
Pilocarpine is a widely used topical mitotic agent used to control the elevated intraocular pressure 
associated with glaucoma, but the drug itself presents significant delivery problems. The rapid loss of 
the drug from the precorneal area via drainage, the low lipophilicity, and the poor permeability across 
the corneal membrane all contribute to the drug’s poor bioavailability, where only 1-3% or less of the 
topically administered dose gains access to the internal eye structure [47-49]. Furthermore, the current 
dosage regimen for pilocarpine is 3-6 times per day, due to the drug short half life. 
For the above reason, a number of lipophilic alkyl and arylalkyl esters of pilocarpic acid were 
synthesized [43-46] and evaluated as prodrugs of pilocarpine. The results obtained suggested that the 
pilocarpic acid esters may be potentially useful prodrugs with enhanced drug delivery and 
bioavailability properties, especially when further derivatized to give non-labile, easily formulated 
pilocarpic acid diesters that convert readily to the parent drug in vivo (Figure 1) [43,44]. In aqueous 
solution the esters undergo a quantitative and apparent specific base-catalyzed lactonization to 
pilocarpine [50]. The cyclization most likely involves pre-equilibrium ionization at the hydroxyl group 
and intramolecular nucleophilic attack of alkoxide ion on the ester carbonyl moiety. It was reported 
that the optimal lipophilicity for improving corneal permeability (i.e., the rate of ocular pilocarpine 
delivery), was observed at log P values of 3-4, but more extensive corneal uptake by the most 
lipophilic prodrugs suggested that the largest ocular bioavailability may be obtained with larger values 
of log PC [51].  
The diester prodrugs were of special interest, since they combine an enhanced bioavailability and 
greatly prolonged duration of action with high stability in eye drop formulations. Some studies 
suggested that, although the corneal permeability of pilocarpine is increased by prodrug derivatives, 
ocular irritation is associated with the in vivo use of these lipophilic prodrugs. The eye irritation of 
pilocarpine prodrugs increased with increasing lipophilicity, pH and concentration.  Such lipophilic 
pilocarpine prodrugs exhibit amphiphilic properties, which may contribute to the ocular irritation of 
these compounds [52]. Furthermore, the ocular delivery of pilocarpine prodrugs may be enhanced 
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while the local irritation can be minimized by appropriately combining buffer, viscosity and 
complexation with polymer formulation approaches [53-55] 
Topically applied β-blockers, which decrease aqueous humor formation by ciliary-body processes, 
are rapidly eliminated from the precorneal area because of their drainage via the nasolacrimal duct, 
dilution by tear turnover, and absorption into the systemic circulation [56,57]. Therefore, the 
usefulness of β-blocking agents in glaucoma has been limited because of respiratory side effects 
[58,59]. An effective approach to improve the ocular delivery of such drugs and to diminish the 
adverse effects is the use of lipophilic prodrugs. Sasaki et al. have studied the ocular delivery of O-
acetyl, O-propionyl, O-butyryl and O-valeryl ester prodrug derivatives of the β-blocker tilisolol, in 
order to decrease intraocular pressure after instillation [60]. All the above prodrugs showed rapid 
enzymatic conversion to tilisolol in ocular tissue homogenates. This rapid conversion was reflected in 
the enhanced delivery of tilisolol through corneal, conjunctival and scleral membranes. These results 
demonstrate the potential utility of lipophilic prodrugs of tilisolol as anti-glaucoma agents. 
 
Figure 1. Pilocarpic acid diesters prodrugs and their hydrolysis in the ocular tissue. 
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Helbreg et al. investigated the ocular metabolism of bimatoprost (Lumigan®), the ethylamide 
prodrug derivative of the potent prostaglandin FP agonist, 17-phenyl-trinor PGF2α, using either 
human or rabbit ocular tissue [61]. The ethylamide group of bimatoprost was hydrolyzed by rabbit and 
human cornea, iris/ciliary body and the sclera to produce the parent drug (Figure 2). These studies 
demonstrated that human and rabbit ocular tissue (cornea, iris/ciliary body and sclera) can convert 
bimatoprost to the potent prostaglandin FP agonist 17-phenyl-trinor PGF2α.  
  
Figure 2. Bimatoprost prodrug and its hydrolysis to the active form, bimatoprost acid, in the eye. 
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Enzymatic regeneration of parent drug in ocular tissue from the prodrug derivative is essential to 
retain activity. Hussain et al. [62] studied the enzymatic regeneration of epinephrine from its prodrug 
ester in rabbit eye homogenate. As expected, the prodrug itself had no activity, while upon enzymic 
regeneration of epinephrine from the prodrug the reaction mixture exhibited α-adrenergic activity.  
Prodrug administration has proven to be an effective method for drug delivery to the anterior 
segment of the eye. Since the cornea is lipid in nature, it is only logical that it would be more 
permeable to a lipophilic prodrug compared to a more polar parent drug. The prodrug would then be 
metabolized by resident enzymes, to the parent compound. Good examples of successfully marketed 
ophthalmic prodrugs are: dipivephrine for the delivery of epinephrine as the dipivalyl ester of 
epinephrine, and bimatoprost, latanoprost and travoprost, which are isopropyl ester prodrugs that are 
prostaglandin F2α analogs. 
 
3b. The Codrug Approach  
 
The same concept has also been employed in a novel codrug design to concomitantly deliver two 
physicochemically different, synergistic drug molecules, which would provide improved physico-
chemical properties compared to a physical combination of the two parent drugs, and provide 
controlled drug release upon hydrolysis in tissue [63,64]. Codrugs or mutual prodrugs contain a 
covalent linker tethering two or more synergistic compounds together in order to improve the drug 
delivery properties of one or both drugs. Like prodrugs, codrugs are bioconvertible derivatives of the 
component active parent compounds. Covalent linkage of a lipophilic angiostatic steroid such as 3α, 
17α, 21-trihydroxy-5β-pregnan-20-one (trihydroxy steroid, THS) to an antiproliferative compound of 
comparatively higher aqueous solubility, such as 5-fluorouracil (5FU), would afford a hydrolysable 
codrug with improved physicochemical properties (i.e. intermediate between the water-insoluble THS 
molecule and the highly water-soluble 5FU molecule) leading to an increase in the bioavailability of 
both parent drugs with an expected increase in angiostatic efficacy.  
A formulation consisting of directly compressed sustained release pellets prepared from material 
consisting of a molecule of THS covalently linked via carbonate moieties to two molecules of 5FU to 
form a novel THS-BIS-5FU codrug (Figure 3) for the treatment of angiogenesis and/or retinal 
detachments resulting from proliferation of fibrovascular networks can be considered as an ocular 
chemical delivery system for delivery of THS and 5FU upon hydrolysis over extended periods of time. 
The codrug hydrolysis profile in different media illustrated the successful regeneration of the parent 
drugs. However, the release of THS was slower than the release of 5FU, since THS generation 
proceeded through a cyclic carbonate intermediate. Results from these studies provide valuable 
information for optimization of the codrug design and pelleted formulation of codrugs in order to 
achieve sustained release for ocular angiogenesis therapy. Hydrolysis kinetics analysis demonstrated 
no detectable levels of the THS-BIS-5FU codrug which illustrated that the rate limiting step is the 
dissolution of the codrug from the pellet, then immediate hydrolysis to regenerate 5FU and a cyclic 
carbonate intermediate that subsequently degrades to THS.  [65]. 
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Figure 3. The THS-BIS-5FU codrug and the hydrolytic pathway for the release of THS and 5FU. 
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Furthermore, Cardillo et al. have reported on a naproxen-5FU codrug system for the treatment of 
experimental post-traumatic proliferative vitreoretinopathy. Their results suggested that this codrug 
system effectively inhibits the progression of experimental proliferative vitreoretinopathy (PVR) in a 
rabbit trauma model that closely resembles PVR in humans [66]. This unique concept of codrug design 
has also been utilized in our laboratories for codrugs of ethacrynic acid (ECA) covalently linked to 
either atenolol (ATL) or timolol (TML) via ester bond linkages (Figure 4) were designed and 
synthesized to improve ocular delivery, and in addition, to take advantage of the apparent synergistic 
mechanism of ECA and the two β-adrenergic receptor antagonists [67]. An important intraocular 
pressure-reducing agent prostaglandin F2α (PGF2α) has low ocular bioavailability.   
Figure 4. The structure of ECA-ATL and ECA-TML codrugs. 
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Cynkowska et al. [68] studied a novel codrug containing PGF2α or PGF2α triacetate linked to a β-
blocker such as timolol (TML) or atenolol (ATL) via an ester moiety to permit hydrolytic cleavage at 
physiological pH with enzymic mediated hydrolysis.  The main goal of this approach was to improve 
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drug delivery by overcoming the water solubility problems of the parent drugs, and to enhance their 
corneal penetration. The PGF2α-TML codrug as well as the PGF2α-ATL codrug successfully 
underwent hydrolysis in vitro to generate PGF2α and TML or ATL, respectively in phosphate buffer 
pH 7.4 and in human serum [68].   
 
4. Enzyme Inhibitors to Modulate Prodrugs transport and metabolism 
 
Utility of enzyme inhibitors to modulate transport and metabolism of prodrugs appears to be 
promising strategy for enhancing drug transport across cornea. Katragadda et al. defined the principle 
enzyme classes responsible for the hydrolysis of the L-valine ester of acyclovir, valacyclovir (VACV) 
and the L-glycine-valine ester of acyclovir, gly-val-acyclovir (GVACV) as carboxylesterases and 
aminopeptidases, respectively.  Hydrolysis studies of VACV and GVACV in corneal homogenate 
were conducted in presence of various enzyme inhibitors.  Complete inhibition of VACV hydrolysis 
was observed in the presence of 4-(2-aminoethyl)benzenesulfonyl fluoride and p-
chloromercuribenzoic acid.  Similar trend was also observed with GVACV in the presence of bestatin 
[69].  
Thus, the prodrug approach offers a wide range of options in drug design and delivery. However, 
to successfully implement these strategies it is important to have an understanding of the distribution 
of the various metabolic enzymes in ocular tissues. The acyclovir prodrugs, valacyclovir and val-
valacyclovir were observed to be substrates of the peptide transporter expressed on the corneal tissue, 
and demonstrated greater permeability when compared to the parent drug [70]. 
In an attempt to enhance corneal drug absorption through prodrug modification targeted to the 
amino acid transporters, Balakrishnan et al. carried out uptake studies using [3H] L-tyrosine at 37 °C 
and showed a major saturable and minor non-saturable component. Competitive inhibition studies 
were performed in the presence of various amino acids and model tyrosine conjugates (i.e. p-nitro and 
p-chloro benzyl ether conjugates of L-tyrosine). Uptake was inhibited by neutral aromatic and large 
neutral aliphatic amino acids. L-Tyrosine uptake was inhibited by its ether conjugates in a 
concentration- dependent manner suggesting that these compounds may be sharing the same transport 
mechanism [71]. 
Transporter-targeted prodrug derivatization was investigated also utilizing quinidine, a model P-
glycoprotein (P-gp) substrate. Results clearly indicated that the L-valine and L-valine-valine prodrug 
esters of quinidine can modulate P-gp-mediated efflux and enhance permeability [72]. These prodrugs 
have a reduced or diminished affinity toward P-gp and were further recognized by the peptide 
transporter-mediated process. Enhanced permeability of the prodrugs indicates that prodrugs can be a 
viable strategy for overcoming P-gp-mediated efflux.  Furthermore, Majumdar et al. studied a series of 
dipeptide monoester ganciclovir (GCV) prodrugs; Val-Val-GCV, Tyr-Val-GCV, and Gly-Val-GCV 
and reported that the transcorneal permeability of Val-GCV and Val-Val-GCV was seven- to eight fold 
greater than that of GCV, in the presence of a proton gradient, and was significantly decreased in the 
presence of Gly-Pro. Val-Val-GCV (1% w/v) provided significantly better therapeutic activity than 
trifluorothymidine (1% w/v) against HSV-1 epithelial keratitis, and equivalent therapeutic activity 
against stromal keratitis in the rabbit eye model. It was found that Val-Val-GCV afforded excellent 
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corneal permeability and chemical stability, high aqueous solubility, and substantial in vivo antiviral 
activity against HSV-1 [73]. 
5. Eye Irritation and Corneal Damage Assessment 
 
Different methodologies were used to assess and evaluate the eye irritation due to topically applied 
prodrugs. Ashton et al. synthesized a group of polyethylene glycol flurbiprofenate prodrugs and 
reported them to cause no corneal damage when tested in albino rabbit eyes and measured by 
differential scanning calorimetry [74]. The eye irritation of the water soluble Cyclosporine A prodrug 
(UNIL-088), a novel Cyclosporine A ester with N-[[1-(acetyloxy)ethoxy]carbonyl]-O-phosphono-L-
seryl-N-methylglycine was assessed by the Draize test and by Confocal Laser Ophthalmoscopy 
(CLSO). The prodrug showed an excellent tolerance for the prodrug solution compared to reference 
cyclosporine oil solution which induced lachrymation and irritation [75]. 
 
Conclusions 
 
Separation of therapeutic effect from toxicity is a valuable goal in the drug development process. 
Careful consideration and understanding of ocular tissue metabolic processes within the eye has 
important implications for controlling the detoxification of therapeutic agents, and for providing the 
potential for site-specific bio-activation of certain prodrugs and codrugs, thus enabling significant 
improvements in efficacy and the minimization of local and systemic side-effects. The prodrug and 
codrug approaches outlined in this review article may provide relevant information to researchers 
involved in designing appropriate and effective delivery systems for the treatment of ocular disorders. 
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